Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Endometrial Neoplasms 1Brain Neoplasms 1

Interventions

Sunitinib 2Paclitaxel 2valrubicin 1temsirolimus 1sipuleucel-T 1luprolide acetate gel depot 1ferumoxtran-10 1abiraterone 1abemaciclib 1Suspensions 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Prednisone 1Prednisolone 1Powders 1Pemetrexed 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Mitomycin 1Magnetic Resonance Spectroscopy 1Leuprolide 1Fatty Acids, Omega-3 1Educational Status 1Docetaxel 1Bevacizumab 1Atorvastatin 1Administration, Intravesical 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urogenital Neoplasms × ferumoxtran-10 × Clear all
NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡